Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia
| Status: | Recruiting |
|---|---|
| Conditions: | Anemia |
| Therapuetic Areas: | Hematology |
| Healthy: | No |
| Age Range: | 1 - 75 |
| Updated: | 12/12/2018 |
| Start Date: | September 9, 2016 |
| End Date: | April 2022 |
| Contact: | Melhem Solh, MD |
| Email: | msolh@bmtga.com |
| Phone: | 404-255-1930 |
A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor
Severe aplastic anemia is a rare and serious form of bone marrow failure related to an
immune-mediated mechanism that results in severe pancytopenia and high risk for infections
and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance
of survival; however, a response rate with just immunosuppression for those patients lacking
suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of
patients are cured, 1/3 are dependent on long term immunosuppression, and the other 1/3
relapse or develop a clonal disorder. Recent studies have shown that using a haploidentical
donor for transplantation has good response rates and significantly lower rates of acute and
chronic GVHD.
immune-mediated mechanism that results in severe pancytopenia and high risk for infections
and bleeding. Patients with matched sibling donors for transplantation have a 80-90% chance
of survival; however, a response rate with just immunosuppression for those patients lacking
suitable HLA-matched related siblings is only 60%. With immunosuppression, only 1/3 of
patients are cured, 1/3 are dependent on long term immunosuppression, and the other 1/3
relapse or develop a clonal disorder. Recent studies have shown that using a haploidentical
donor for transplantation has good response rates and significantly lower rates of acute and
chronic GVHD.
Mismatched haploidentical donors will be identified for patients with severe aplastic anemia.
These patients will undergo a preparative regimen of Fludarabine/Cyclophosphamide/TBI
followed by haploidentical bone marrow transplantation. Post-transplant Cyclophosphamide will
be administered on Days 3 & 4. Immunosuppression with Tacrolimus and MMF will begin on Day
+5; MMF will be discontinued on Day +35 while Tacrolimus continues until Day +180.
Investigators hypothesize that haploidentical transplantation with the above-mentioned
preparative regimen will have a <30% graft failure rate. The one-sided exact Binomial test at
5% significance level will be used to test this hypothesis. The size of 20 patients provides
the power of 92.5% for confirming the 30-day graft failure rate <30%.
These patients will undergo a preparative regimen of Fludarabine/Cyclophosphamide/TBI
followed by haploidentical bone marrow transplantation. Post-transplant Cyclophosphamide will
be administered on Days 3 & 4. Immunosuppression with Tacrolimus and MMF will begin on Day
+5; MMF will be discontinued on Day +35 while Tacrolimus continues until Day +180.
Investigators hypothesize that haploidentical transplantation with the above-mentioned
preparative regimen will have a <30% graft failure rate. The one-sided exact Binomial test at
5% significance level will be used to test this hypothesis. The size of 20 patients provides
the power of 92.5% for confirming the 30-day graft failure rate <30%.
Inclusion Criteria:
- Availability of 3/6 - 5/6 matched (HLA-A, B, DR) related donor who must have negative
HLA cross-match in the host vs. graft direction
- Age <= 65 years for previously treated and <= 75 years for previously treated patients
- KPS >= 70%
- Aplastic Anemia that meets the following criteria:
Peripheral Blood (must fulfill 2 of 3):
- <500 PMN/mm3
- <20,000 platelets
- absolute reticulocyte count <40,000/microL
Bone Marrow (must be either):
- markedly hypocellular (<25% of normal cellularity)
- moderately hypocellular with 70% non-myeloid precursors and patient meets peripheral
blood criteria above
Exclusion Criteria:
- poor cardiac function (LVEF <40%)
- poor pulmonary function (FEV1 & FVC <50% predicted)
- poor liver function (bili >= 2mg/dL)
- poor renal function (creatinine >= 2.0mg/dL or creatinine clearance <40mL/min)
- prior allogeneic transplant
We found this trial at
2
sites
1000 Johnson Ferry Rd NE
Atlanta, Georgia 30342
Atlanta, Georgia 30342
(404) 851-8000
Phone: 404-255-1930
Northside Hospital Northside Hospital-Atlanta (in Sandy Springs) opened in 1970. The original facility had 250...
Click here to add this to my saved trials
Click here to add this to my saved trials